These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 37022974)

  • 21. Progress Toward Polio Eradication - Worldwide, January 2019-June 2021.
    Bigouette JP; Wilkinson AL; Tallis G; Burns CC; Wassilak SGF; Vertefeuille JF
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1129-1135. PubMed ID: 34437527
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Review of use of inactivated poliovirus vaccine in campaigns to control type 2 circulating vaccine derived poliovirus (cVDPV) outbreaks.
    Estivariz CF; Kovacs SD; Mach O
    Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A113-A121. PubMed ID: 35365341
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation.
    Duintjer Tebbens RJ; Hampton LM; Thompson KM
    BMC Infect Dis; 2016 May; 16():231. PubMed ID: 27230071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission.
    Thompson KM; Duintjer Tebbens RJ
    BMC Infect Dis; 2015 Sep; 15():376. PubMed ID: 26382234
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The risk of type 2 oral polio vaccine use in post-cessation outbreak response.
    McCarthy KA; Chabot-Couture G; Famulare M; Lyons HM; Mercer LD
    BMC Med; 2017 Oct; 15(1):175. PubMed ID: 28974220
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Type 2 Poliovirus Detection after Global Withdrawal of Trivalent Oral Vaccine.
    Blake IM; Pons-Salort M; Molodecky NA; Diop OM; Chenoweth P; Bandyopadhyay AS; Zaffran M; Sutter RW; Grassly NC
    N Engl J Med; 2018 Aug; 379(9):834-845. PubMed ID: 30157398
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiple independent emergences of type 2 vaccine-derived polioviruses during a large outbreak in northern Nigeria.
    Burns CC; Shaw J; Jorba J; Bukbuk D; Adu F; Gumede N; Pate MA; Abanida EA; Gasasira A; Iber J; Chen Q; Vincent A; Chenoweth P; Henderson E; Wannemuehler K; Naeem A; Umami RN; Nishimura Y; Shimizu H; Baba M; Adeniji A; Williams AJ; Kilpatrick DR; Oberste MS; Wassilak SG; Tomori O; Pallansch MA; Kew O
    J Virol; 2013 May; 87(9):4907-22. PubMed ID: 23408630
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016.
    Hampton LM; Farrell M; Ramirez-Gonzalez A; Menning L; Shendale S; Lewis I; Rubin J; Garon J; Harris J; Hyde T; Wassilak S; Patel M; Nandy R; Chang-Blanc D;
    MMWR Morb Mortal Wkly Rep; 2016 Sep; 65(35):934-8. PubMed ID: 27606675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Progress Toward Polio Eradication - Worldwide, January 2018-March 2020.
    Chard AN; Datta SD; Tallis G; Burns CC; Wassilak SGF; Vertefeuille JF; Zaffran M
    MMWR Morb Mortal Wkly Rep; 2020 Jun; 69(25):784-789. PubMed ID: 32584798
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progress Toward Polio Eradication - Worldwide, January 2017-March 2019.
    Greene SA; Ahmed J; Datta SD; Burns CC; Quddus A; Vertefeuille JF; Wassilak SGF
    MMWR Morb Mortal Wkly Rep; 2019 May; 68(20):458-462. PubMed ID: 31120868
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Updated Characterization of Outbreak Response Strategies for 2019-2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain.
    Kalkowska DA; Pallansch MA; Wilkinson A; Bandyopadhyay AS; Konopka-Anstadt JL; Burns CC; Oberste MS; Wassilak SGF; Badizadegan K; Thompson KM
    Risk Anal; 2021 Feb; 41(2):329-348. PubMed ID: 33174263
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Virologic Monitoring of Poliovirus Type 2 after Oral Poliovirus Vaccine Type 2 Withdrawal in April 2016 - Worldwide, 2016-2017.
    Diop OM; Asghar H; Gavrilin E; Moeletsi NG; Benito GR; Paladin F; Pattamadilok S; Zhang Y; Goel A; Quddus A
    MMWR Morb Mortal Wkly Rep; 2017 May; 66(20):538-542. PubMed ID: 28542124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating vaccine-derived polioviruses: current state of knowledge.
    Kew OM; Wright PF; Agol VI; Delpeyroux F; Shimizu H; Nathanson N; Pallansch MA
    Bull World Health Organ; 2004 Jan; 82(1):16-23. PubMed ID: 15106296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Introduction of Inactivated Poliovirus Vaccine and Switch from Trivalent to Bivalent Oral Poliovirus Vaccine - Worldwide, 2013-2016.
    Immunization Systems Management Group of the Global Polio Eradication Initiative
    MMWR Morb Mortal Wkly Rep; 2015 Jul; 64(25):699-702. PubMed ID: 26135591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Update on vaccine-derived polioviruses - worldwide, July 2012-December 2013.
    Diop OM; Burns CC; Wassilak SG; Kew OM;
    MMWR Morb Mortal Wkly Rep; 2014 Mar; 63(11):242-8. PubMed ID: 24647401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outbreak of type 2 vaccine-derived poliovirus in Nigeria: emergence and widespread circulation in an underimmunized population.
    Wassilak S; Pate MA; Wannemuehler K; Jenks J; Burns C; Chenoweth P; Abanida EA; Adu F; Baba M; Gasasira A; Iber J; Mkanda P; Williams AJ; Shaw J; Pallansch M; Kew O
    J Infect Dis; 2011 Apr; 203(7):898-909. PubMed ID: 21402542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progress Toward Poliomyelitis Eradication - Worldwide, January 2022-December 2023.
    Geiger K; Stehling-Ariza T; Bigouette JP; Bennett SD; Burns CC; Quddus A; Wassilak SGF; Bolu O
    MMWR Morb Mortal Wkly Rep; 2024 May; 73(19):441-446. PubMed ID: 38753550
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progress Toward Poliomyelitis Eradication - Worldwide, January 2021-March 2023.
    Lee SE; Greene SA; Burns CC; Tallis G; Wassilak SGF; Bolu O
    MMWR Morb Mortal Wkly Rep; 2023 May; 72(19):517-522. PubMed ID: 37167156
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emergence of vaccine-derived poliovirus type 2 after using monovalent type 2 oral poliovirus vaccine in an outbreak response, Philippines.
    Alipon SB; Takashima Y; Avagyan T; Grabovac V; Aslam SK; Bayutas B; Logronio J; Wang X; Shrestha A; Neupane S; Roces MC; Apostol LN; Sucaldito N
    Western Pac Surveill Response J; 2022; 13(2):1-7. PubMed ID: 36276175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modelling the spread of serotype-2 vaccine derived-poliovirus outbreak in Pakistan and Afghanistan to inform outbreak control strategies in the context of the COVID-19 pandemic.
    Molodecky NA; Jafari H; Safdar RM; Ahmed JA; Mahamud A; Bandyopadhyay AS; Shukla H; Quddus A; Zaffran M; Sutter RW; Grassly NC; Blake IM
    Vaccine; 2023 Apr; 41 Suppl 1():A93-A104. PubMed ID: 34629206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.